Precision-Based Genomics in Prostate Cancer
About this study
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene mutations in men with prostate cancer as well as the course of their disease to better understand how gene mutations relate to the way the cancer progresses and responds to treatment. Eligibility: Adult males 18 and older with prostate cancer who have at least one of the gene mutations researchers want to study and/or have been treated for their cancer and have had complete elimination of their cancer or stable disease for a long time. Design: Participants will be screened with a review of their medical records. Their gene test results will be reviewed, if available. They will be asked questions over the phone or in person. Participants do not need to visit the NIH for this study. But if they visit NIH for another study, their data and test results will be collected. They may give blood and urine samples. They may give leftover tumor samples. These samples will be used to study their genes. Participants who do not come to NIH on regular basis will be contacted every 6 months by phone or e-mail. They will be asked questions about their health. Data from their medical records will be collected. Participants will have testosterone and prostate-specific antigen (PSA) tests. Participants may be invited to NIH to give blood samples for research. Participants on this study will be followed for life.
- Condition
- Prostate Cancer
- Sponsor
- National Cancer Institute (NCI)
Who can join
- Age
- 18 to 120 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 10
- Minimum age: 18 years
- Maximum age: 120 years
- Eligible sex: Male
- Study condition: Prostate Cancer
- Subjects with histologically confirmed prostate cancer.
- Must have known germline and/or somatic variants in PIK3 and/or AKT, PALB2, BRIP1, RAD50, RAD51, RAD54, RB1, SPOP, Wnt/B-catenin pathway, CDK12, and/or MMR genes: MLH1, MSH2, MSH6, PMS2, and EPCAM and/or TMB-high(\[defined as greater than or equal to 10 mutations/megabase (mut/Mb) and/or bTMB \[greater than or equal to 16 mut/Mb\].
- NOTE: any platform for genomics testing is acceptable (research or CLIA-certified)
- be deemed an exceptional responder. NOTE: an exceptional response is defined as achievement of either a) a complete response, or b) a confirmed partial response in a trial or treatment or a response of exceptionally long duration
- Age greater than or equal to 18 years old.
- Ability of subject to understand and the willingness to sign a written informed consent document.
Where
11 sites, 11 recruiting
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Dana Farber Cancer Institute, Boston, MA
Boston, Massachusetts, United States
NorthShore University HealthSystem
Evanston, Illinois, United States
University of California San Diego
La Jolla, California, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University of California San Francisco
San Francisco, California, United States
and 5 more sites on ClinicalTrials.gov
Contact
-
Katherine O Lee-Wisdom, R.N.
(240) 858-3525 katherine.lee-wisdom@nih.gov
-
Fatima H Karzai, M.D.
(301) 480-7174 fatima.karzai@nih.gov
Potential match only. Final eligibility is determined by the study team.